Paper Details

  1. Home
  2. Paper Details

Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the "Ph1-negative Myeloproliferative Neoplasms Latium Group".

Author: AnaclericoBarbara, AndrianiAlessandro, BaldacciErmina, BrecciaMassimo, CedroneMichele, CiminoGiuseppe, Di VeroliAmbra, LatagliataRoberto, MazzucconiMaria Gabriella, MontanaroMarco, MontefuscoEnrico, PaoloniFrancesca, PorriniRaffaele, RagoAngela, SantoroCristina, ScaramucciLaura, SpadeaAntonio, SpiritoFrancesca, VillivàNicoletta

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

This study evaluated the real-life use of anagrelide in patients with essential thrombocythemia (ET) over 25 years.
Paper Details　
Original Abstract of the Article :
Anagrelide is a drug effective in reducing platelet counts in essential thrombocythemia (ET) and Ph1-negative myeloproliferative neoplasms. The aim of this study was to evaluate the real-life use of anagrelide in patients with ET followed over 25 years at the Haematological Institutes belonging to "...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/ejh.13454

データ提供：米国国立医学図書館（NLM）

Anagrelide: A Long-Standing Ally in the Treatment of Essential Thrombocythemia

Essential thrombocythemia (ET) is a blood disorder characterized by an overproduction of platelets, the tiny cells that help blood clot. This study examines the long-term use of anagrelide, a drug used to reduce platelet counts in ET patients. It's like a careful observer studying the effects of a particular herb on the body over a long period of time.

Anagrelide's Effectiveness over Time

The researchers analyzed data from 150 ET patients who were treated with anagrelide for 25 years, a testament to the drug's long-standing use in clinical practice. The study confirmed the effectiveness of anagrelide in managing platelet counts, providing valuable insights into its long-term effects.

Implications for ET Treatment

The findings of this study underscore the importance of long-term studies in understanding the effects of medications. This information can help guide treatment decisions for patients with ET and improve their quality of life.

Dr. Camel's Conclusion

This study is a reminder that the journey towards understanding and treating chronic diseases is a continuous one. Anagrelide's effectiveness over 25 years provides valuable insights for managing ET and highlights the importance of long-term research in medicine.

Date :
  1. Date Completed 2021-06-16
  2. Date Revised 2021-06-16
Further Info :

Pubmed ID

32441419

DOI: Digital Object Identifier

10.1111/ejh.13454

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.